DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML

BACKGROUND: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors, 5-azacytidine and 5-aza-2′-deoxycytidine (decitabine), benefit some MDS/AML patients. However, the role of DNA methyltransferase inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lund, Kirstin, Cole, John J, VanderKraats, Nathan D, McBryan, Tony, Pchelintsev, Nikolay A, Clark, William, Copland, Mhairi, Edwards, John R, Adams, Peter D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165364/
https://www.ncbi.nlm.nih.gov/pubmed/25315154
http://dx.doi.org/10.1186/s13059-014-0406-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165364/
https://www.ncbi.nlm.nih.gov/pubmed/25315154
http://dx.doi.org/10.1186/s13059-014-0406-2

Ejemplares similares